ABSTRACT OBJECTIVES This study investigated the cost effectiveness of early cardiac resynchronization therapy (CRT) implantation among patients with mild heart failure (HF). The differential cost effectiveness between CRT using a defibrillator (CRT-Ds) and CRT using a pacemaker (CRT-P) was also assessed.
Importantly, long-term follow-up (11) enabled several analyses (12) that, along with enhanced statistical techniques (13) (14) (15) , addressed many issues regarding the cost effectiveness of CRT in mild HF.
METHODS
TRIAL POPULATION. REVERSE enrolment criteria have been detailed elsewhere (11) . In short, 610
North American and European subjects were randomized. Key inclusion criteria included NYHA functional classes I/II HF, QRS $120 ms, left ventricular ejection fraction #40%, and optimal medical therapy (OMT) for HF. Subjects received CRT devices that were randomly assigned (2:1) to be "CRT-ON" or "CRT-OFF." Randomization ended when all patients had CRT programmed "ON" at pre-specified post-implantation timing (12 months in North America and 24 months in Europe). The trial was approved by an institutional review committee, and all subjects gave informed consent (NCT00271154).
ECONOMIC MODEL DESIGN.
A "proportionin-state" model, with a 1-month cycle length was used to evaluate lifetime costs and benefits (16, 17) . Health states were defined by survival ("alive" and "dead") and NYHA functional class. Given the dataset's very small number of class IV patients at any time, this subgroup was combined with class III patients.
All patients received biventricular pacing devices, with the controls having CRT initially off, whereas some received implants with a combined biventricular pacing and defibrillator device. All patients designated "alive"
were assumed to receive OMT regardless of NYHA functional class. A 3-stage process was subsequently implemented, using statistical models generated and previously published in REVERSE outcome extrapolation (13) . The primary outcome measure was incremental cost effectiveness ratio (ICER), defined as the cost to offer an additional quality-adjusted life year (QALY).
Discounting of 3% was applied (18) . Probabilistic sensitivity analysis (PSA) was undertaken in main and subgroup analyses, using 1,000 Monte Carlo simulations. Cost effectiveness acceptability curves (CEACs) were also provided. Mean PSA results were presented with 95% credible intervals (CrIs). The model was coded in Excel 2010 software (Microsoft Corp., Redmond, Washington).
MORTALITY, HF DISEASE PROGRESSION AND HF
HOSPITALIZATION. Analytical methods to estimate survival, disease progression, and HF hospitalization have been detailed elsewhere (13) . In summary, statistical techniques (19) used for the first time in cardiology allowed an estimate of how CRT-OFF patients would have performed had they not turned biventricular pacing "ON" at the pre-specified time points. 
DEVICE-RELATED ADVERSE
EVENTS. Adverse events (AEs) for patients who received a biventricular pacing device were based on clinical trial data over the full follow-up period. All patients were used to calculate these rates, regardless of randomization allocation. Adverse event rates were assumed to be zero for patients not receiving biventricular pacing in this analysis; they were assumed to happen immediately after implantation and were paid at the same rate as for HF-related hospitalization. Adverse events actually observed during implantation were assumed to be covered within the implantation. Post-implant device-related AE rate 10.56% 36 *The value was selected because of customary reasons and without any particular reference (it is common for these analyses to employ monthly cycles).
AE ¼ adverse event; CRT-D ¼ cardiac resynchronization defibrillator; CRT-P ¼ cardiac resynchronization pacemaker; HF ¼ heart failure; ICD ¼ implantable cardioverter-defibrillator; NYHA ¼ New York Heart Association.
results. For each parameter, 95% confidence intervals (CI) were used to inform the uncertainty estimate. In the absence of CIs, we used the simplifying assumption that the standard error was 10% of the mean. Beta distributions were used to quantify uncertainty in utility values. Log-normal distributions were used for uncertainty in device longevity and cost/resource parameters. Relationships between coefficients in all regression equations were maintained within the PSA via the use of multinomial distributions. Table S3 ).
ADDITIONAL SENSITIVITY ANALYSES. Univariate deterministic sensitivity analyses were run with mean device longevities, acquisition costs, and NYHA functional class utilities being varied by AE10%. 
The impact of these analyses was marginal (highest

DISCUSSION
The benefit of CRT in HF with a reduced ejection fraction is well established (2-4,7-9) and is part of the updated U.S. and E.U. guidelines for device-based therapy (26, 27) . However, this therapy's cost effectiveness has been primarily demonstrated only in advanced HF (5, 6) , and these studies have several limitations. HF therapy has high initial costs, which may yield a cost effectiveness underestimation whenever the study duration is shorter than generator battery lifespan. Most of these studies were not double-blinded, which may influence treatments.
Cost comparisons of CRT-P and ICD devices have not 
ICER Threshold below which Technology is Accepted
All pa ents Ischemics LBBB Morphology QRS Dura on <138ms QRS Dura on >=138ms
Abbreviations as in Figure 1 . To address these issues, a detailed analysis of REVERSE was performed. REVERSE was designed to ensure double-blinding and to maximize bias mitigation (14, 15) . We used the preplanned 5-year follow-up phase of this trial (11) MADIT-CRT (10) showed improved cost effectiveness among the subgroup with LBBB, which guidelines suggest is the subgroup most likely to benefit from LYG ¼ Life Years Gained; other abbreviations as in Tables 1 and 2 . Abbreviations as in Figure 1 .
CRT. Recent studies have suggested that QRS duration may be more important than QRS morphology (i.e., bundle branch type) (30) . Thus, the benefit noted in REVERSE is important if further studies support CRT guideline broadening as the cost effectiveness was noted with all subjects included.
Probabilistic methods were used to include and quantify the uncertainty around results. Probabilistic sensitivity analysis revealed that CRT likely is a cost effective option compared to nonbiventricular pacing. Cardiac resynchronization therapy with a defibrillator, even if the average ICER compared to CRT-P is close to the $50,000/QALY threshold, the probability exceeded is < 10%. As battery longevity continues to improve, CRT-Ds are highly likely to be more cost effective in this patient population.
Cardiac resynchronization therapy with pacemakers (4) and CRT-Ds (3,9) have been shown to reduce mortality among patients with HF with a reduced ejection fraction and QRS prolongation. More recent studies have shown that pacing at LV sites with late mechanical or electrical activation are associated with better outcomes (36, 37) . Of the 346 patients with implant location data, 66.18% (n ¼ 229)
had lateral LV leads, and 71% had nonapical locations.
We did not adjust for implant location in our analyses. Therefore, the results may underestimate the cost effectiveness of CRT when newer techniques to choose implant locations are used.
For the "early" versus "late" analysis, we assumed patients who received implants when progressing to class III, received benefits (and costs) mimicking those of CRT-ON. With CRT-ON patients being class I/II at time of implantation, we might have overestimated the benefits associated with delayed implantation and been biased against early implantation.
The limitations of the extrapolated clinical data we used have been described previously (13) .
The applicability of the statistical models used has TRANSLATIONAL OUTLOOK: These data can be used to inform optimal decision making in patients with a guidelinebased indication for device implantation. They can also be used as important inputs in environments where economic value plays a role, especially alternative payment models gradually being introduced.
